Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.
Dan Riskin
Advertisement
Articles by Dan Riskin
Applied Clinical Trials
The FDA has been working to enable greater adoption of RWE in clinical and regulatory decisions, as mandated by the 21st Century Cures Act.
Advertisement
Latest Updated Articles
- How to Transition RWE Studies from Non-Clinical to Regulatory-Grade
January 10th 2019
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny
2
ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy
3
Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development
4
Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif
5